Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

NCT04079179 is registered in ClinicalTrials.gov with Carl Allen as lead sponsor.

NCT NCT04079179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04079179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.
Lead sponsor
Carl Allen
Phase
Phase 2
Overall status
Recruiting
Start date
April 19, 2021
Completion date
December 31, 2029
Enrollment
90 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

erdheim-chester disease, histiocytic disorders, malignant, histiocytic sarcoma, juvenile xanthogranuloma, langerhan's cell histiocytosis, neuro-degenerative disease, rosai dorfman disease